179 related articles for article (PubMed ID: 14666430)
1. EPO-906 (Novartis).
Galmarini CM; Dumontet C
IDrugs; 2003 Dec; 6(12):1182-7. PubMed ID: 14666430
[TBL] [Abstract][Full Text] [Related]
2. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
3. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
4. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
5. Epothilones: mechanism of action and biologic activity.
Goodin S; Kane MP; Rubin EH
J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
[TBL] [Abstract][Full Text] [Related]
6. Patupilone in cancer treatment.
Bystricky B; Chau I
Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
[TBL] [Abstract][Full Text] [Related]
7. PTK/ZK (Novartis).
Drevs J
IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
[TBL] [Abstract][Full Text] [Related]
8. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
9. Activity of epothilones.
Kolman A
Curr Opin Investig Drugs; 2005 Jun; 6(6):616-22. PubMed ID: 15988913
[TBL] [Abstract][Full Text] [Related]
10. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
12. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol. National Cancer Institute.
Wang HK
Curr Opin Investig Drugs; 2001 Aug; 2(8):1149-55. PubMed ID: 11892928
[TBL] [Abstract][Full Text] [Related]
14. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
15. Edotecarin.
Denny WA
IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
[TBL] [Abstract][Full Text] [Related]
16. BMS-310705 Bristol-Myers Squibb/GBF.
Kolman A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1292-7. PubMed ID: 15648951
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
18. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: GEM-231, Hybridon.
Yeung PK
Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
[TBL] [Abstract][Full Text] [Related]
20. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
